MS Cure - Monash Uni, page-16

Since we are allegedly talk facts here, referring to the news story above, the role of ATL 1102 is not to "trick cells into rebuilding themselves" it is to inhibit the VLA-4 receptor on T cells and reduce the effects of inflammation. It is that mechanism that constrains the progress of the disease and in many ways the same effect that constrains the progress of DMD. It is neither a cure for MS or DMD. In relation to animal based trials, according to Nature BioTech in 2014, the likelihood of success through to regulatory approval for drugs successfully tested in animals is around 5%. In terms of time, given everything else that needs to happen, there is at least 10 years of effort, trialling and approval and so Monash have a ways to go even to translate this into a suitable drug candidate for a small safety trial that could be Ph1.

That is the reality of glacial progress in biotech and what investors sign up for. Traders are another thing all together.